Effects of nebivolol on human platelet aggregation

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 6, 2001, Pages 922-929

  Falciani, Maddalena ^a,b   Rinaldi, Barbara ^a   D'Agostino, Bruno ^a   Mazzeo, Filomena ^a   Rossi, Settimio ^a   Nobili, Brúno ^a   Rossi, Francesco ^a   Filippelli, Amelia ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Section of Pharmacology   (Italy)

Author keywords

Carvedilol; L arginine; NG monomethyl L arginine; Nebivolol; Platelet aggregation; Propranolol

Indexed keywords

ADENOSINE DIPHOSPHATE; ARGININE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; COLLAGEN; N(G) METHYLARGININE; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROPRANOLOL;

ADULT; ARTICLE; DRUG EFFECT; DRUG MECHANISM; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TURBIDIMETRY; VASODILATATION;

ADENOSINE DIPHOSPHATE; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; ARGININE; BENZOPYRANS; BLOOD PLATELETS; CARBAZOLES; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; ETHANOLAMINES; HUMANS; MALE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROPANOLAMINES; PROPRANOLOL; VASODILATOR AGENTS;

EID: 0035196271     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200112000-00014     Document Type: Article

References (28)

1. The pathogenesis of atherosclerosis (second of two parts)
2. Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol
3. Effect of propranolol on platelet function
4. Beta-adrenoceptor antagonists and human platelets: Relationship of effects to lipid solubility
5. Pharmacological properties of nebivolol in man
6. Nebivolol in the management of essential hypertension
7. Nebivolol induces endothelium-dependent relaxations in canine coronary arteries
8. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism
9. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension
10. The Larginine-nitric oxide pathway
11. Endothelium-derived relaxant factor inhibits platelet activation
12. In vivo EDRF activity influences platelet function
13. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets
14. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets
15. Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets
16. Expression of constitutive endothelial nitric oxide synthase in human blood platelets
17. An L-arginine to nitric oxide pathway present in human platelets regulates aggregation
18. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects
19. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men
20. Aggregation of blood platelets by adenosine diphosphate and its reversal
21. Platelet aggregation in hypertension and the effects of antihypertensive treatment
22. Antihypertensive therapy: The unanswered question
23. Platelet-derived nitric oxide and coronary risk factors
24. Comparison of the effects of carvedilol, propranolol and verapamil on in vitro platelet function in healthy volunteers
25. Nitric oxide mediated venodilator effects of nebivolol
26. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
27. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells
28. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol